EXPERIENCE IN THE USE OF PLASMAPHERESIS IN ACUTE INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY GUILLAIN – BARRE SYNDROME IN THE PATIENT WITH CHRONIC HEPATITIS C VIRUS INFECTION AND TYPE 2 DIABETES MELLITUS

Acute inflammatory demyelinating polyneuropathy Guillain – Barre syndrome (AIDP-GB) – acquired immune mediated disease with acute onset characterized by the development of peripheral tetraparesis due to immune system attack to peripheral nerves and spinal roots. This article describes the case report of AIDP-GB development in the patient with hepatitis C and type 2 diabetes mellitus. The patient was treated with course of plasmapheresis and subsequent course of intravenous immunoglobulin (IVIG) for increasing the effectiveness of therapy. During the therapy, there was a significant improvement in the condition of patient and reduction of neurological deficit, confirmed by neurological examination and electroneuromyography, immediately after treatment and in 6 months. In addition, rehabilitation measures for the patient included physical therapy, including physiotherapy and acupuncture. To sum up, the effective treatment of AIDP-GB includes pathogenic therapy (plasmapheresis, IVIG) and rehabilitation measures to facilitate the recovery of the patient and return to professional practice.

acute inflammatory demyelinating polyneuropathy, Guillain – Barre syndrome, hepatitis C, diabetes mellitus, plasmapheresis, immunoglobulin, rehabilitation

1. Burns TM. Guillain-Barre syndrome. Semin Neurol. 2008;28(2):152-67.

2. Gunatilake SSC, Gamlath R, Wimalaratna H. An unusual case of recurrent Guillain-Barré syndrome with normal cerebrospinal fluid protein levels: A case report. BMC Neurol. 2016;16(1):1 —5. Available at: http://dx.doi.org/10.1186/s12883-016-0687-z

3. Willison HJ, Jacobs BC, van Doom PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-27.

4. Sipila JOT, Soilu-Hanninen M, Ruuskanen JO, Rautava P, Kyto V Epidemiology of Guillain-Barré syndrome in Finland 2004-2014. JPeripherNerv Syst. 2017 ;22(4):440-5.

5. Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y Current topics in therapeutic plasmapheresis. Clin Exp Nephrol. 2014;18(1):41-9.

6. Kleyman I, Brannagan TH. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Curr Neurol Neurosci Rep. 2015;15(7).

7. Szczepiorkowski ZM, Winters JL, Bandarenko N et al. Guidelines On the Use Of Therapeutic Apheresis In Clinical Practice-Evidence Based Approach from the Aphe- resis Applications Committee of the American Society of Apheresis. Journl of Clinical Apheresis 2010; 25: 83-177.

8. Order of Ministry of Health and Social Development of Russian Federation from 24.04.2006 «About standart of medical help to patients with inflammatory polyneuropathies confirmation» (In Russ.).

9. All-Russian Neurology Society. Clinical Recommen¬dations for diagnostics and treatment of Guillain-Barre Syndrome. 2014: 1-23 (In Russ.).

10. Guillain-Barre Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain- Barre syndrome. Lancet. 1993;341:586-90.

11. van Koningsveld R, Schmitz PIM, Van Der Meche FG a, Visser LH, Meulstee J, Van Doom P a. Effect of me- thylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: Randomised trial. Lancet. 2004;363(9404):192-6.

12. Voinov VA. Efferent therapy. Membrane plasmaphe¬resis. Fifth edition, revised. - Moscow, OAO «Novosti», 2010: 368 p. (In Russ.).

13. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 1987; 22 (6): 753-61.

14. The Guillain-Barré syndrome Study Group. Plasma-pheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology. 1985;35(8):1096-104.

15. Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guil- lain-Barre syndrome. Neurology. 1998;51(3):875-7.

16. Prasad HB, Borse RT, Avate AN, Palasdeokar N. Prognostic indicators of response to plasmapheresis in pati¬ents of Guillain Barre syndrome. J Assoc Physicians India. 2017; 65(APRIL):32-6.

17. French Cooperative Group on Plasma Exchange in Guil-lain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol 1997; 41 (3): 298-306.

18. Tombak A, Uçar MA, Akdeniz A, Yilmaz A, Kaleagasi H, Sungur MA, et al. Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases. Indian J Hematol Blood Transfus. 2017;33(1):97-105.

19. van der Meche FGA, Schitz PIM. A Randomized Trial Comparing IVIG and Plasma Exchange in GBS. Nejm. 1993.

20. Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain Barre syndrome. J Assoc Physi¬cians India. 2013;61(3):168-72. Available at: http://www. ncbi.nlm.nih.gov/pubmed/24475678

21. Plasma Exchange/Sandoglobulin Guillain-Barré Syn¬drome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997; 349(9047):225-30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9014908

22. The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre Syndrome with High-Dose Immune Globulins Combined with Methylprednisolone: A Pilot Study. The New England Journal of Medicine. 1994;326: 1126-1129.

23. Niazi MA, Azhar A, Tufail K, Feyssa EL, Penny SF, McGregory M, et al. Guillain-barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report. World J Hepatol. 2010;2(4):162-6.

24. Lacaille F, Zylberberg H, Hagège H, Roualdès B, Meyrignac C, Chousterman M, et al. Hepatitis C associated with Guillain-Barré syndrome. Liver. 1998; 18(1):49-51. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9548267

25. Bae JS, Kim YJ, Kim JK. Diabetes mellitus exacerbates the clinical and electrophysiological features of Guillain- Barré syndrome. Eur J Neurol. 2016;23(3):439-46.

26. Wang Y, Li G, Yang S, Gu X, Li X, Liu M, et al. Fasting glucose levels correlate with disease severity of guillain-barré syndrome. PLoS One. 2015;10(12):1-9.

27. Inokuchi H, Yasunaga H, Nakahara Y, Horiguchi H, Ogata N, Fujitani J, et al. Effect of rehabilitation on mortality of patients with Guillain-Barre Syndrome: a propensity- matched analysis using nationwide database. Eur J Phys Rehabil Med. 2014;50(4):439-46. Available at: http://www. ncbi.nlm.nih.gov/pubmed/24651152

28. Alexandrescu R, Siegert RJ, Turner L. Functional out-comes and efficiency of rehabilitation in a national cohort of patients with Guillain-Barré syndrome and other inflam¬matory polyneuropathies. PLoS One. 2014; 9 (11): e110532.

29. Simatos Arsenault N, Vincent P-O, Yu BHS, Bastien R, Sweeney A. Influence of Exercise on Patients with Guillain- Barré Syndrome: A Systematic Review. Physiother Canada. 2016;68(4):367-76. Available at: http://utpjournals.press/ doi/10.3138/ptc.2015-58

30. Khan F, Pallant JF, Amatya B et al. Outcomes Of High- And Low-Intensity Rehabilitation Programme for Persons in Chronic Phase After Guillain-Barre Syndrome: A Rndomised Controlled Trial. J Rehabil Med. 2011; 43: 638-646.

31. Garssen MPJ, Bussman JBJ, Schitz PIM et al. Physical training and fatigue, fitness , and quality of life in Guillain- Barré syndrome and CIDP. Neurology. 2004;63:2393-6.

32. Bussmann JB, Garssen MP, van Doom PA et al. Analy-sing The Favourable Effects Of Physical Exercise: Relationships Between Physical Fitness, Fatigue and Functioning in Guillain- Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy. J Rehabil Med. 2007; 39: 121-125.

33. Orsini M, de Freitas M, Presto B et al. Guideline for Neuromuscular Rehabilitation in Guillain-Barre Syndrome: What Can We Do? Rev Neuroscienc. 2010; 18(4): 572-580

34. Voinov VA. Efferent therapy of neurologic diseases. Spb: SpbGMU press, 2014: 38 p. (In Russ.).